Mineralys Therapeutics, Inc. (MLYS)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$20.55-4.29%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Mineralys Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.606
Annual ending 2026-12-31
Revenue	—	557,143
EPS	—	-4.484
Annual ending 2027-12-31
Revenue	—	87.83M
EPS	—	-2.393

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
EPS loss narrowing trajectory	A supporting condition in Mineralys Therapeutics, Inc.'s published investment case. The stated target is EPS loss improves from -0.56 next quarter to less negative by FY27.	Broken	EPS loss worsens or remains flat through FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful commercial launch of lorundrostat	Mineralys is advancing the commercial launch of lorundrostat, a key product.	Intact	failure to advance commercial launch milestones through FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 2 quarters. Management confirmed commercial launch preparations are on track for lorundrostat with a PDUFA target date of December 22, 2026. Cash and investments remain sufficient to fund operations including the launch into 2028. The trajectory is delivering as planned toward launch readiness. Delivery assessment Oct 24, 2026
Finalize agreement to terminate future royalty payments	The company aims to finalize an agreement to end future royalty payments, improving capital allocation.	Recovered	no agreement finalized by end of 2026	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-2.39

$-2.10 → $-2.39 · observed estimates

FY2027 revenue$0.09B

$0.12B → $0.09B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-2.10	$121,384,897	6 / 6
2026-07-25	$-2.10	$121,384,897	6 / 6
2026-07-26	$-2.10	$121,384,897	6 / 6
2026-07-27	$-2.10	$121,384,897	6 / 6
2026-07-28	$-2.10	$121,384,150	8 / 8
2026-07-29	$-2.10	$121,384,150	8 / 8
2026-07-30	$-2.10	$121,384,150	8 / 8
2026-07-31	$-2.10	$121,384,150	8 / 8
2026-08-01	$-2.10	$121,384,147	6 / 6
2026-08-02	$-2.10	$121,384,150	8 / 8
2026-08-03	$-2.10	$121,384,150	8 / 8
2026-08-04	$-2.10	$121,384,150	8 / 8
2026-08-05	$-2.10	$121,384,147	6 / 6
2026-08-06	$-2.10	$121,384,150	8 / 8
2026-08-07	$-2.10	$121,384,147	6 / 6
2026-08-08	$-2.10	$121,384,150	8 / 8
2026-08-09	$-2.10	$121,384,150	8 / 8
2026-08-10	$-2.10	$121,384,150	8 / 8
2026-08-12	$-2.10	$121,384,147	6 / 6
2026-08-13	$-2.10	$121,384,147	6 / 6
2026-08-14	$-2.10	$121,384,147	6 / 6
2026-08-15	$-2.10	$121,384,147	6 / 5
2026-08-16	$-2.10	$121,384,147	6 / 5
2026-08-17	$-2.10	$121,384,147	6 / 5
2026-08-18	$-2.10	$121,384,147	6 / 6
2026-08-19	$-2.10	$121,384,147	6 / 6
2026-08-20	$-2.43	$88,688,396	6 / 6
2026-08-21	$-2.43	$88,688,396	6 / 6
2026-08-22	$-2.43	$88,688,396	6 / 6
2026-08-23	$-2.43	$88,688,396	6 / 6
2026-08-24	$-2.43	$88,688,396	6 / 6
2026-08-25	$-2.43	$88,688,396	6 / 6
2026-08-26	$-2.43	$88,688,396	6 / 6
2026-08-27	$-2.43	$88,688,396	6 / 6
2026-08-28	$-2.43	$88,688,396	6 / 6
2026-08-29	$-2.43	$88,688,396	6 / 6
2026-08-30	$-2.43	$88,688,396	6 / 6
2026-08-31	$-2.43	$88,688,396	6 / 6
2026-09-01	$-2.43	$88,688,396	6 / 6
2026-09-02	$-2.43	$88,688,396	6 / 6
2026-09-03	$-2.43	$88,688,396	6 / 6
2026-09-04	$-2.43	$88,688,396	6 / 6
2026-09-05	$-2.43	$88,688,396	6 / 6
2026-09-06	$-2.43	$88,688,396	6 / 6
2026-09-07	$-2.43	$88,688,396	6 / 6
2026-09-08	$-2.43	$88,688,396	6 / 6
2026-09-09	$-2.43	$88,688,396	6 / 6
2026-09-10	$-2.43	$88,688,396	6 / 6
2026-09-11	$-2.43	$88,684,546	6 / 6
2026-09-12	$-2.43	$88,684,546	6 / 6
2026-09-13	$-2.43	$88,684,546	6 / 6
2026-09-14	$-2.43	$88,684,546	6 / 6
2026-09-15	$-2.43	$88,684,546	6 / 6
2026-09-16	$-2.43	$88,684,546	6 / 6
2026-09-17	$-2.43	$88,684,546	6 / 6
2026-09-18	$-2.43	$88,684,546	6 / 6
2026-09-19	$-2.43	$88,684,546	6 / 6
2026-09-20	$-2.43	$88,684,546	6 / 6
2026-09-21	$-2.43	$88,684,546	6 / 6
2026-09-22	$-2.43	$88,684,546	6 / 6
2026-09-23	$-2.43	$88,684,546	6 / 6
2026-09-24	$-2.43	$88,684,546	6 / 6
2026-09-25	$-2.43	$88,684,546	6 / 6
2026-09-26	$-2.43	$88,684,546	6 / 6
2026-09-27	$-2.43	$88,684,546	6 / 6
2026-09-28	$-2.43	$88,684,546	6 / 6
2026-09-29	$-2.43	$88,684,546	6 / 6
2026-09-30	$-2.43	$88,684,546	6 / 6
2026-10-01	$-2.43	$88,684,546	6 / 6
2026-10-02	$-2.43	$88,684,546	6 / 6
2026-10-03	$-2.43	$88,684,546	6 / 6
2026-10-04	$-2.43	$88,684,546	6 / 6
2026-10-05	$-2.43	$88,684,546	6 / 6
2026-10-06	$-2.43	$88,684,546	6 / 6
2026-10-07	$-2.43	$88,684,546	6 / 6
2026-10-08	$-2.43	$88,684,546	6 / 6
2026-10-09	$-2.43	$88,684,546	6 / 6
2026-10-10	$-2.43	$88,684,546	6 / 6
2026-10-11	$-2.43	$88,688,396	6 / 6
2026-10-12	$-2.43	$88,688,396	6 / 6
2026-10-13	$-2.39	$87,833,306	7 / 6
2026-10-14	$-2.39	$87,833,306	7 / 6
2026-10-15	$-2.39	$87,833,306	7 / 6
2026-10-16	$-2.39	$87,833,306	7 / 6
2026-10-17	$-2.39	$87,833,306	7 / 6
2026-10-18	$-2.39	$87,833,309	7 / 6
2026-10-19	$-2.39	$87,833,309	7 / 6
2026-10-20	$-2.39	$87,833,309	7 / 6
2026-10-21	$-2.39	$87,833,309	7 / 6
2026-10-22	$-2.39	$87,833,309	7 / 6
2026-10-23	$-2.39	$87,833,309	7 / 6
2026-10-24	$-2.39	$87,833,309	7 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	9	1
2026-06-01	9	1
2026-07-01	9	1
2026-08-01	9	1
2026-09-01	9	1
2026-10-01	9	2

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 9 Buy / Strong Buy · 2 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

UBSOct 11

$29.00New observation · no comparable prior

$0$15.95$31.90

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

EPS loss narrowing trajectoryPublished status: Broken
Successful commercial launch of lorundrostatDirect metric needs a verified mapping
Finalize agreement to terminate future royalty paymentsDirect metric needs a verified mapping

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

1.7%Typical daily move · historical

Downside history

-57.1%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Mineralys Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative growth business, not an established earnings compounder, because it remains loss-making and recent financial performance is weak. The long-term thesis is in a watch state: launch preparations are on track, but execution and near-term results remain uncertain.

What's priced into Mineralys Therapeutics, Inc.

The snapshot provides no valuation measure or explicit account of market expectations, so whether MLYS is cheap or expensive versus peers cannot be assessed. Its loss-making status and elevated risk are clear, but the evidence does not show how much expectation for lorundrostat's launch is already reflected.

What the fundamentals likely do

Near term, erratic earnings and a recent quarterly miss leave meaningful risk of another miss, while management's stable cash position supports operations into 2028. For the multi-year thesis, the key planned change is lorundrostat's commercial launch, targeted for December 22, 2026, with preparations reported on track.

What Mineralys Therapeutics, Inc. hinges on

The thesis depends on reaching launch readiness and converting that launch into stronger business performance, while maintaining enough funding. A guidance cut or further weakening in employment data could weigh on the near-term outlook; continued strength at healthcare bellwethers could support sector sentiment, but would not establish MLYS's own execution.